Enhanced Melphalan Formulations with Integrated Technologies for Personalized Cancer Treatment
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates the patented stable melphalan formulations with cutting-edge technologies such as AI, IoT, blockchain, and novel biomaterials to create a more effective and personalized system for cancer treatment.
Background and Problem Solved
The original patent provided stable ready-to-use injectable formulations of melphalan. However, the limitations of the original patent lie in its inability to optimize treatment outcomes, monitor degradation, and ensure supply chain integrity. The present inventive concept addresses these limitations by incorporating advanced technologies to enhance the overall system.
Detailed Description of the Inventive Concept
The inventive concept comprises a melphalan formulation with enhanced stability against degradation, an AI-based dosing algorithm for optimizing treatment outcomes based on patient-specific data, IoT-enabled sensors for real-time monitoring and controlling of degradation, a blockchain-based supply chain management system for tracking and verifying the authenticity of melphalan formulations, a nanocarrier-based delivery system for melphalan, and a smart packaging system comprising a novel biomaterial that monitors and responds to environmental factors affecting the stability of the drug.
Novelty and Inventive Step
The new claims introduce the synergistic combination of melphalan formulations with AI, IoT, blockchain, and novel biomaterials, which provides a non-obvious and novel solution for personalized cancer treatment, supply chain management, and real-time monitoring of degradation.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, various IoT sensor configurations, and diverse blockchain platforms. Additionally, the nanocarrier-based delivery system could be modified to accommodate different biomaterials and targeting mechanisms.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized cancer treatment, supply chain management, and real-time monitoring of degradation. The target market includes pharmaceutical companies, hospitals, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/08 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/198 |
| A | A61 | A61K47/10 |
| A | A61 | A61K47/183 |
| A | A61 | A61K47/32 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations, drug delivery systems, and medical technology with a focus on injectable cancer treatments, requiring advanced knowledge of pharmaceutical chemistry, biotechnology, and medical device engineering
Person of Ordinary Skill (PHOSITA) Profile
A professional with a PhD in pharmaceutical sciences or chemical engineering, expertise in drug stability, formulation technologies, and advanced medical delivery systems, with 5-10 years of industry or research experience
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies and advanced materials with established pharmaceutical formulations represents a predictable evolution of drug delivery systems. The core melphalan formulation remains fundamentally unchanged from the source patent, while the proposed technological enhancements represent logical extensions of existing pharmaceutical innovation strategies. The combination of AI, IoT, and blockchain with drug delivery represents a natural progression of personalized medicine technologies that a skilled practitioner would find straightforward to conceptualize and implement.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,677 |
|---|---|
| Title | Ready to use injectable formulations of melphalan and processes for preparation thereof |
| Assignee(s) | RK PHARMA INC. |